Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H27FN2O |
Molecular Weight | 378.4824 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)[C@]1(CC[C@@]2(CC1)OCCC3=C2NC4=CC=C(F)C=C34)C5=CC=CC=C5
InChI
InChIKey=CSMVOZKEWSOFER-RQNOJGIXSA-N
InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3/t23-,24-
Molecular Formula | C24H27FN2O |
Molecular Weight | 378.4824 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24713140Curator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/25147603
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24713140
Curator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/25147603
Cebranopadol is a novel analgesic nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonist. Cebranopadol, by its combination of agonism at NOP and opioid receptors, affords highly potent and efficacious analgesia in various pain models with a favorable side effect profile. Cebranopadol displays analgesic, antiallodynic and antihyperalgesic properties in several rat models of acute nociceptive, inflammatory, cancer and neuropathic pain. Unlike morphine, cebranopadol did not disrupt motor coordination and respiration at doses within and exceeding the analgesic dose range possessing a broader therapeutic window than classical opioids. It is currently in clinical development for the treatment of severe chronic nociceptive and neuropathic pain.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P41146 Gene ID: 4987.0 Gene Symbol: OPRL1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25147603 |
13.0 nM [EC50] | ||
Target ID: P35372|||G8XRH8|||Q5TDA1|||Q9UN57 Gene ID: 4988.0 Gene Symbol: OPRM1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25147603 |
1.2 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
891 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28623508 |
1200 μg 1 times / day steady-state, oral dose: 1200 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CEBRANOPADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1119 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28623508 |
1600 μg 1 times / day steady-state, oral dose: 1600 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CEBRANOPADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
255 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28623508 |
400 μg 1 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CEBRANOPADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14474 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28623508 |
1200 μg 1 times / day steady-state, oral dose: 1200 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CEBRANOPADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
18785 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28623508 |
1600 μg 1 times / day steady-state, oral dose: 1600 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CEBRANOPADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4260 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28623508 |
400 μg 1 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CEBRANOPADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors. | 2015 Jun |
|
Simultaneous targeting of multiple opioid receptor types. | 2015 Jun |
|
Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. | 2015 Mar |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 23:54:37 UTC 2022
by
admin
on
Fri Dec 16 23:54:37 UTC 2022
|
Record UNII |
7GDW9S3GN3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C241
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ZZ-140
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
C112002
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
863513-91-1
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
DTXSID001031965
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
11848225
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
DB12830
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
7GDW9S3GN3
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
9631
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
CHEMBL2364605
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY | |||
|
Cebranopadol
Created by
admin on Fri Dec 16 23:54:37 UTC 2022 , Edited by admin on Fri Dec 16 23:54:37 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET | |||
|
TARGET -> AGONIST |
BINDING
Ki
|
||
|
TARGET -> AGONIST |
BINDING
Ki
|
||
|
TARGET -> AGONIST |
BINDING
Ki
|
||
|
TARGET -> AGONIST |
BINDING
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |